8/6/2013

Isis Pharmaceuticals is halting development of its investigational drug ISIS-CRPRx as a treatment for rheumatoid arthritis based on the findings of a Phase II study. The drug failed to significantly outperform a placebo in the alleviation of symptoms. The firm will continue to develop the drug for other diseases, including atrial fibrillation.

Full Story:
Reuters

Related Summaries